The U.S. Solicitor General has urged the Supreme Court to reverse a recent decision regarding the Hikma ‘skinny label’ case, a ruling that could significantly impact the generic drug market. The Solicitor General argues that this decision threatens to undermine a crucial pathway that allows for the expedited entry of new generic drugs, which is vital for maintaining competitive pricing and access to medications.
This case highlights the ongoing tension between brand-name pharmaceutical companies and generic manufacturers. The ‘skinny label’ provision enables generics to enter the market without infringing on certain patents, thereby facilitating competition. If the Supreme Court sides with the lower court’s decision, it could set a precedent that restricts the ability of generics to launch products effectively, potentially leading to higher drug prices and reduced availability for healthcare providers.
Use the database as your supply chain compass →
